Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170043/S023

Glaukos iStent inject W Trabecular Micro-Bypass System, Glaukos iStent inject W Trabecular Micro-Bypass System with

Glaukos Corporation · Decision date Oct 1, 2026

MEDTECHLEDGER EXPLANATIONP170043/S023

What did the FDA decide?

FDA posted a 30-Day Notice decision for supplement S023 to PMA P170043 for the Glaukos iStent inject W Trabecular Micro-Bypass System. The decision record lists four changes: moving the Instructions for Use from printed to electronic format, updating the sustainable shipper box, reducing the incoming inspection sampling plan for the Trocar component, and adding an alternative location for final packaging, labeling, and lot release operations on the existing manufacturing campus.

The supplement is categorized as a process change involving manufacturer, sterilizer, packager, or supplier. The posted statement does not describe any change to the device design, indications, or clinical data, and it does not provide evidence of safety or effectiveness. Specific details about the alternative location, the revised sampling plan parameters, or the shipper box update are absent from the source statement.

FDA approval order statement

four changes including Instruction for Use change from printed to electronic format, updated sustainable shipper box, reduced incoming inspection sampling plan for Trocar component, and addition of alternative location for final packaging, labeling and lot release operations on the existing manufacturing campus
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Oct 1, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170043/S023
Regulatory pathway
PMA supplement
Product code
OGO
Decision code
OK30
Decision date
Oct 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Intraocular pressure lowering implant.

Product code
OGO
FDA device class
3

For the original device and its historical approval scope, see PMA P170043. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170043 · Original PMA

    iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)

  2. P170043/S023 received

    Application receipt date recorded by FDA.

  3. P170043/S023 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P170043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170043

Product / regulatory recordCompanyPathwayDecision dateSource
Glaukos CorporationPMA approvalJun 21, 2018FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Glaukos Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
229 Avenida Fabricante, San Clemente, CA, 92672

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records